Provided by Tiger Trade Technology Pte. Ltd.

Medicus Pharma Ltd.

0.0921
-0.0098-9.62%
Post-market: 0.0845-0.0076-8.25%19:48 EDT
Volume:17.32M
Turnover:1.77M
Market Cap:5.82M
PE:-0.06
High:0.0948
Open:0.0865
Low:0.0840
Close:0.1019
52wk High:2.78
52wk Low:0.0840
Shares:63.18M
Float Shares:46.69M
Volume Ratio:3.74
T/O Rate:37.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6597
EPS(LYR):-2.7356
ROE:-7446.11%
ROA:-110.67%
PB:-3.30
PE(LYR):-0.03

Loading ...

Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company

THOMSON REUTERS
·
Sep 08

Medicus Pharma - Cd228v Established as Principal Strategic Priority for Medicus Pharma

THOMSON REUTERS
·
Sep 08

Medicus Pharma Pivots to Precision Oncology, Prioritizing Cd228v Melanoma Proof-of-Concept Study

Reuters
·
Sep 08

U.S. Stocks on the MOVE-Gold Miners, Polestar Automotive, Nvidia

Reuters
·
Sep 03

Medicus Pharma Shares Down 20.5% Premarket; Co, Pfizer Enter Licensing Deal for Experimental Cancer Therapy

THOMSON REUTERS
·
Sep 03

Medicus Pharma Secures Global Pfizer License for CD228V

TIPRANKS
·
Sep 03

Medicus Pharma Surges on Pfizer Licensing Deal for Experimental Cancer Therapy

Reuters
·
Sep 03

Medicus Pharma Signs Co-Development, Licensing Deal with Pfizer for Cd228v Antibody-Drug Conjugate

Reuters
·
Sep 03

Medicus Pharma - Pays Pfizer $12 Mln Upfront, $15 Mln Due on First Anniversary - SEC Filing

THOMSON REUTERS
·
Sep 03

Medicus Pharma - Pfizer Paid the Company a One-Time, Non-Refundable Payment of $2.0 Million

THOMSON REUTERS
·
Sep 03

Medicus Pharma - Enters Co-Development and License Agreement with Pfizer on Sept 2, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 03

Medicus Pharma Advances SkinJect and Teverelix Amid Financing Gains and Going-Concern Risk

TIPRANKS
·
Aug 13

Medicus Pharma Ltd Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

Medicus Pharma Q2 EPS $(0.21) Misses $(0.13) Estimate

Benzinga Earnings
·
Aug 13

Medicus Pharma Q2 EPS USD -0.21

THOMSON REUTERS
·
Aug 13

Medicus Pharma Q2 Operating Expenses USD 11.5 Million

THOMSON REUTERS
·
Aug 13

Medicus Pharma FY26 Q2 Net Loss Widens 89.1% to $11.68 Million

Reuters
·
Aug 13

Medicus Pharma Ltd Expected to Post a Loss of 13 Cents a Share - Earnings Preview

Reuters
·
Aug 08

Medicus UK Unit Antev Names Faisal Mehmud CEO Effective Aug. 30

Reuters
·
Aug 03

Medicus Pharma Appoints DR. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom

THOMSON REUTERS
·
Aug 03